Mintz, M.D
Metformin (long-term) : Associated with B12 malabsorption code E53.8 or use drug-induced nutritional deficiency coding
3 The microenvironment of hepatocellular carcinoma The tumor microenvironment (TME) plays a crucial role in various stages of cancer progression, including the initiation of cancer, epithelial-mesenchymal transition (EMT), invasion, and metastasis
Potential Benefits FDA-approved for HIV-associated lipodystrophy (Egrifta, 2010): the only GHRH analogue with a completed phase 3 regulatory programme and an approved indication Selective visceral fat reduction: clinical trials demonstrated significant reductions in intra-abdominal adipose tissue (IAAT) compared to placebo, with minimal effect on subcutaneous fat Preserves lean muscle mass: the pulsatile GH secretion mechanism avoids the muscle catabolism associated with caloric restriction alone Improves lipid profiles: reductions in triglycerides and improvements in HDL cholesterol have been observed in clinical trial populations Supports insulin sensitivity in patients without baseline glucose impairment: distinguished from direct GH injection which can worsen glucose tolerance Pulsatile GH secretion: preserves physiological release patterns rather than producing the sustained supraphysiological GH levels associated with exogenous GH use Documented IGF-1 elevation: measurable and trackable via standard blood tests, providing a clinical biomarker for treatment response and dose appropriateness Well-characterised side effect profile from phase 3 data: injection site reactions, fluid retention, and joint discomfort are the primary effects and are generally mild and reversible Physician-supervised protocols with COA-verified, clinical-grade sourcing: not dispensed as a grey-market research peptide through this clinic Video consultation available nationwide in Thailand, with physician-prescribed protocols and cold-chain delivery to Bangkok, Phuket, Chiang Mai, and all regions Speak with a physician Interested in Tesamorelin
(2024), intravesicular (bladder) injections of BPC-157 were reported to result in 80100% resolution of moderate to severe interstitial cystitis at 6 weeks post- treatment
